Synairgen plc

LSE SNG.L

Synairgen plc Operating Cash Flow for the year ending December 31, 2023: USD -10.46 M

Synairgen plc Operating Cash Flow is USD -10.46 M for the year ending December 31, 2023, a 38.83% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Synairgen plc Operating Cash Flow for the year ending December 31, 2022 was USD -17.10 M, a 69.19% change year over year.
Synairgen plc Operating Cash Flow for the year ending December 31, 2021 was USD -55.49 M, a -70.81% change year over year.
Synairgen plc Operating Cash Flow for the year ending December 31, 2020 was USD -32.49 M, a -754.24% change year over year.
Synairgen plc Operating Cash Flow for the year ending December 31, 2019 was USD -3.80 M, a -77,983.86% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

LSE: SNG.L

Synairgen plc

CEO	Mr. Richard Marsden
IPO Date	Oct. 26, 2004
Location	United Kingdom
Headquarters	Mailpoint 810
Employees	36
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Key trends

Past 5 years